"Invasive bladder cancer" trang 1 - tải miễn phí từ tailieunhanh
Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: A protocol for a randomized controlled trial

Efficacy and safety of transurethral resection of bladder tumour combined with chemotherapy and immunotherapy in bladder-sparing therapy in patients with T1 high-grade or T2 bladder cancer: A protocol for a randomized controlled trial
8    4    1
Management of non-muscle-invasive bladder cancer: Quality of clinical practice guidelines and variations in recommendations

Management of non-muscle-invasive bladder cancer: Quality of clinical practice guidelines and variations in recommendations
12    114    0
Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: A comparison of two sequencing methods and gene sets using FFPE specimens

Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: A comparison of two sequencing methods and gene sets using FFPE specimens
10    5    1
Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis

Comparison of 3 and 4 cycles of neoadjuvant gemcitabine and cisplatin for muscle-invasive bladder cancer: A systematic review and meta-analysis
12    6    1
Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer

Promoter hypermethylation of HS3ST2, SEPTIN9 and SLIT2 combined with FGFR3 mutations as a sensitive/specific urinary assay for diagnosis and surveillance in patients with low or high-risk non-muscleinvasive bladder cancer
9    83    1
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier

Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: Mechanism of action of P-MAPA biological response modifier
18    83    1
Protocol of the Italian Radical Cystectomy Registry (RIC): A non-randomized, 24- month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer

Protocol of the Italian Radical Cystectomy Registry (RIC): A non-randomized, 24- month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer
9    48    1
Down-regulation of A-FABP predicts nonmuscle invasive bladder cancer progression: Investigation with a long term clinical follow-up

Down-regulation of A-FABP predicts nonmuscle invasive bladder cancer progression: Investigation with a long term clinical follow-up
13    55    1
Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: A retrospective non-randomized comparative study

Non-maintenance intravesical Bacillus Calmette–Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: A retrospective non-randomized comparative study
11    50    1
Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: A multicenter retrospective study

Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: A multicenter retrospective study
8    26    1
Urinary UBC rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: Results from a prospective single-center study

Urinary UBC rapid and NMP22 test for bladder cancer surveillance in comparison to urinary cytology: Results from a prospective single-center study
9    511    0
ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes

ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk “BCG failure” non muscle invasive bladder cancer: 3 years follow-up outcomes
9    75    1
Ebook Comprehensive textbook of genitourinary oncology (4/E): Part 1

Ebook Comprehensive textbook of genitourinary oncology (4/E): Part 1
523    89    0
Utility of SAM68 in the progression and prognosis for bladder cancer

Utility of SAM68 in the progression and prognosis for bladder cancer
8    52    1
High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer

High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer
10    79    1
Laminin-integrin a6b4 interaction activates notch signalling to facilitate bladder cancer development

Laminin-integrin a6b4 interaction activates notch signalling to facilitate bladder cancer development
11    25    1
Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities

Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities
9    96    0
Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer

Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer
9    67    0
Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer

Androgen receptor mRNA expression is a predictor for recurrence-free survival in non-muscle invasive bladder cancer
6    65    0
Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: A phase II trial

Adjuvant radiotherapy after radical cystectomy for patients with muscle invasive bladder cancer: A phase II trial
6    81    1